Comparison tool

Compare peptides

Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.

Select up to three (1/3)

Comparison results

Attribute
CategoryGrowth hormone
Evidence gradeStrong
Also known asEgrifta, TH9507
MechanismA stabilised GHRH(1-44) analogue that resists enzymatic degradation, producing a sustained, physiological increase in endogenous GH and downstream IGF-1.
Key benefitsClinically demonstrated visceral adipose tissue reduction (~15–18%) · Improved triglycerides in trial populations · Preliminary evidence for cognitive benefit in older adults
Side effectsJoint pain and swelling · Injection-site erythema · Insulin resistance · Peripheral oedema
Half-life26–38 minutes
AdministrationDaily subcutaneous injection, abdomen
Dosing overviewApproved label dose is 2 mg once daily
StorageRefrigerated; reconstitute immediately before use per label
Legal statusFDA-approved for a specific indication; other uses are off-label.

Dosing figures reflect published literature and commonly reported community protocols. They are informational only.

Head-to-head comparisons

Each comparison below is its own page with the full attribute table, key differences and shared attributes for that pairing. They are grouped by the category the compounds are indexed under.

GLP-1 receptor agonists

Direct comparisons between the incretin-based compounds most often searched against one another.

Recovery and tissue repair

Pairings between compounds indexed for healing, connective tissue and post-injury recovery.

Growth-hormone axis

Secretagogues and releasing peptides that act on growth-hormone signalling, compared with each other and with adjacent compounds.

Longevity and mitochondrial

Compounds indexed under longevity, cellular and mitochondrial function.

Cognitive and nootropic

Peptides indexed for cognition and mood-related use.

Sexual health

Melanocortin and related compounds indexed for sexual-health use.